(ORKA) Oruka Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.530m USD | Total Return: 393.4% in 12m
Avg Turnover: 69.8M
Warnings
Share dilution 32.4% YoY
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Confidence
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biopharmaceutical firm based in Menlo Park, California, specializing in monoclonal antibody therapies. The company’s pipeline focuses on chronic inflammatory and immunology (I&I) disorders, specifically targeting the interleukin pathways associated with psoriasis and psoriatic arthritis.
The companys lead candidates, ORKA-001 and ORKA-002, are currently undergoing Phase 2 clinical trials. These programs aim to provide therapeutic alternatives in the highly competitive I&I sector, where biological treatments often require high manufacturing scalability and precise targeting of inflammatory cytokines. The biotechnology sector frequently utilizes such monoclonal antibodies to achieve higher specificity and reduced off-target effects compared to traditional systemic treatments.
For more detailed data on clinical milestones and market positioning, ValueRay provides comprehensive analytical tools. Oruka is also advancing ORKA-003 and a combination regimen, ORKA-021, to expand its presence within the autoimmune therapeutic landscape.
- Clinical trial data readouts for ORKA-001 and ORKA-002 drive investor sentiment
- Success of IL-23 and IL-17 inhibitors determines competitive positioning in psoriasis market
- High research and development expenditures necessitate future capital raises and equity dilution
- Regulatory approval timelines for monoclonal antibody candidates impact long-term valuation
- Strategic partnerships or acquisition potential by major biopharmaceutical firms influences share price
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 2.44 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -90.9m > Net Income -116.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 23.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.2m) vs 12m ago 32.37% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 395.2m - Total Current Liabilities 16.6m) / Total Assets 504.5m |
| B: -0.44 (Retained Earnings -221.0m / Total Assets 504.5m) |
| C: -0.29 (EBIT TTM -125.7m / Avg Total Assets 440.8m) |
| D: 27.41 (Book Value of Equity 486.7m / Total Liabilities 17.8m) |
| Altman-Z'' = 30.35 = AAA |
As of June 06, 2026, the stock is trading at USD 60.14 with a total of 1,281,990 shares traded.
Over the past week, the price has changed by +2.75%,
over one month by -12.78%,
over three months by +81.31% and
over the past year by +393.36%.
Oruka Therapeutics has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy ORKA.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 142.2 | 136.4% |
P/B = 7.2967
Revenue TTM = 0.0 USD
EBIT TTM = -125.7m USD
EBITDA TTM = -125.6m USD
Long Term Debt = 1.13m USD (estimated: total debt 1.81m - short term 680k)
Short Term Debt = 680k USD (from shortTermDebt, last quarter)
Debt = 1.81m USD (from shortLongTermDebtTotal, last quarter) (leases 1.81m already included)
Net Debt = -387.0m USD (calculated: Debt 1.81m - CCE 388.8m)
Enterprise Value = 3.14b USD (3.53b + Debt 1.81m - CCE 388.8m)
Interest Coverage Ratio = unknown (Ebit TTM -125.7m / Interest Expense TTM 0.0)
EV/FCF = -34.47x (Enterprise Value 3.14b / FCF TTM -91.2m)
FCF Yield = -2.90% (FCF TTM -91.2m / Enterprise Value 3.14b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 83.0k) / Revenue TTM)
Tobins Q-Ratio = 6.23 (Enterprise Value 3.14b / Total Assets 504.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.81m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -99.3m (EBIT -125.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 23.76 (Total Current Assets 395.2m / Total Current Liabilities 16.6m)
Debt / Equity = 0.00 (Debt 1.81m / totalStockholderEquity, last quarter 486.7m)
Debt / EBITDA = 3.08 (negative EBITDA) (Net Debt -387.0m / EBITDA -125.6m)
Debt / FCF = 4.24 (negative FCF - burning cash) (Net Debt -387.0m / FCF TTM -91.2m)
Total Stockholder Equity = 447.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.37% (Net Income -116.3m / Total Assets 504.5m)
RoE = -25.99% (Net Income TTM -116.3m / Total Stockholder Equity 447.3m)
RoCE = -28.04% (EBIT -125.7m / Capital Employed (Equity 447.3m + L.T.Debt 1.13m))
RoIC = -20.33% (negative operating profit) (NOPAT -99.3m / Invested Capital 488.5m)
WACC = 9.07% (E(3.53b)/V(3.53b) * Re(9.07%) + D(1.81m)/V(3.53b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 81.58%
[DCF] Fair Price = unknown (Cash Flow -91.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.50 | Chg30d=+7.30% | Revisions=+38% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.51 | Chg30d=+11.39% | Revisions=+54% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.04 | Chg30d=+8.14% | Revisions=+54% | GrowthEPS=-10.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.46 | Chg30d=+7.63% | Revisions=+50% | GrowthEPS=-20.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +54%